Contract manufacturing organisation (CMO) Onyx Scientific has formed an alliance with UK-based Reach Separations, which will allow the firm to deliver more specialist purification and separation services.
As part of the deal, Onyx Scientific will now offer custom separation for companies in drug discovery and intermediate environments. This includes chiral, reverse phase and normal phase chromatography using Supercritical Fluid Chromatography (SFC) and High Performance Liquid Chromatography (HPLC).
Reach Separations is located in BioCity in Nottingham, one of Europe’s largest bioscience incubators, which currently hosts more than 70 companies and has a rich heritage in drug discovery.
With MHRA and FDA licensed facilities in the UK and India, Sunderland-based Onyx Scientific supports pharmaceutical and biotech companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large-scale commercial API production.
Denise Bowser, commercial director at Onyx Scientific, said: ‘We expect this strategic partnership will play an important role in giving our clients quicker access to these types of services but with the added benefit of knowing it will be managed by us as part of the overall project.’
Reach Separations’s technical director Phil Abbott added: ‘We are delighted to be working alongside Onyx Scientific given the company’s fine reputation in contract medicinal chemistry, scale-up and manufacturing for the world’s drug development industry.
‘We have strong experience in the pharmaceutical outsourcing sector so understand the challenges and issues clients face. Our role will be to bring our expertise to the table and work as part of the Onyx team to ensure clients’ requirements are always met and timelines never exceeded.’
